BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
ABBV upcoming catalysts
AbbVie: 10 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (4 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 35 readout(s) and 14 FDA event(s). Subscribe to ABBV (.ics).
Drugs: ABBV-RGX-314, Upadacitinib, Lutikizumab, Venetoclax, Ranibizumab, Bevacizumab, Livmoniplimab, Budigalimab, Mirvetuximab Soravtansine, Topical Steroid, Aflibercept, Adalimumab, ABBV-400, Folinic Acid, Fluorouracil, Irinotecan, Durvalumab, Atezolizumab, Tremelimumab, Azacitidine, IMGN632, Lubricating, Prednisolone acetate ophthalmic suspension 1%, Brimonidine tartrate ophthalmic, MEDI0618, Ravagalimab, Dupilumab, Lenvatinib, Sorafenib, Carboplatin, Obinutuzumab, AGN-151586, Risankizumab, Pomalidomide, Dexamethasone
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2/P3 | AbbVie ABBV | NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; Wet AMD; CNV; Neovascular AMD; Neovascular Ag | active not recruiting | 671 |
| 2026-12 est. | P2 | AbbVie ABBV | NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Met | Unresectable Metastatic Colorectal Cancer | active not recruiting | 280 |
| 2026-12 est. | P3 | AbbVie ABBV | NCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | active not recruiting | 1400 |
| 2027-01 est. | P2/P3 | AbbVie ABBV | NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as a | Hepatocellular Carcinoma | active not recruiting | 89 |
| 2027-01 est. | P3 | AbbVie ABBV | NCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe | Atopic Dermatitis | active not recruiting | 99 |
| 2027-02 est. | P1/P2 | AbbVie ABBV | NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Acute Myeloid Leukemia | active not recruiting | 218 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Fol | Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive | active not recruiting | 108 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receivin | Hidradenitis Suppurativa; Atopic Dermatitis | recruiting | 60 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | Migraine | active not recruiting | 309 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | recruiting | 180 |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | AbbVie ABBV | NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anx | Generalized Anxiety Disorder (GAD) | recruiting | 315 |
| 2026-11 est. | P3 | AbbVie ABBV | NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | Atopic Dermatitis | active not recruiting | 184 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab | Hepatocellular Carcinoma | active not recruiting | 130 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Canc | High Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer | active not recruiting | 125 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic | Chronic Lymphocytic Leukemia (CLL) | recruiting | 75 |
| 2026-10-13 | P2 | AbbVie ABBV | NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-Related Macular Degeneration (nAMD) | active not recruiting | 146 |
| 2026-10 est. | P2 | AbbVie ABBV | NCT07730554 A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants | Forehead Lines | active not recruiting | 84 |
| 2026-10 est. | P3 | AbbVie ABBV | NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; WetAMD; CNV | active not recruiting | 735 |
| 2026-09-03 | P3 | AbbVie ABBV | NCT07032597 A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants | Mid Face Volume Deficit | completed | 252 |
| 2026-09 est. | P3 | AbbVie ABBV | NCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Recei | Juvenile Psoriatic Arthritis | recruiting | 40 |
| 2026-08-21 | P3 | AbbVie ABBV | NCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participan | Dry Eye Disease | completed | 261 |
| 2026-08-17 | P2 | AbbVie ABBV | NCT03339128 Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children | Irritable Bowel Syndrome | completed | 272 |
| 2026-08 est. | P3 | AbbVie ABBV | NCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Partici | Multiple Myeloma | active not recruiting | 265 |
| 2026-07-27 | P2 | AbbVie ABBV | NCT06236880 A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD | Major Depressive Disorder | completed | 126 |
| 2026-07-19 est. | P3 | AbbVie ABBV | NCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis | Ulcerative Colitis (UC) | withdrawn | |
| 2026-07-15 | P3 | AbbVie ABBV | NCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Se | Rheumatoid Arthritis | completed | 487 |
| 2026-07-14 | P3 | AbbVie ABBV | NCT05995340 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars | Atrophic Acne Scars | completed | 157 |
| 2026-07 est. | P2 | AbbVie ABBV | NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritone | Advanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancers | recruiting | 110 |
| 2026-07 est. | P2 | AbbVie ABBV | NCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | active not recruiting | 270 |
| 2026-06-29 | P3 | AbbVie ABBV | NCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | Menstrual Migraine (MM) | active not recruiting | 468 |
| 2026-06-19 | P3 | AbbVie ABBV | NCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | Open-Angle Glaucoma; Ocular Hypertension | completed | 455 |
| 2026-06-18 | P2 | AbbVie ABBV | NCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular | Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME) | completed | 139 |
| 2026-05 est. | P1/P2 | AbbVie ABBV | NCT03933735 A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | active not recruiting | 220 |
| 2026-04-27 | P3 | AbbVie ABBV | NCT04750226 Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkin | Parkinson's Disease (PD) | completed | 118 |
| 2026-04-17 | P3 | AbbVie ABBV | NCT04379050 Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkins | Parkinson's Disease (PD) | completed | 130 |
| 2026-04-03 | P3 | AbbVie ABBV | NCT06794866 A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult P | Forehead Lines | completed | 150 |
| 2026-02-05 | P2/P3 | AbbVie ABBV | NCT06547125 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Qual | Skin Quality Deficit | completed | 135 |
| 2026-02-04 | P3 | AbbVie ABBV | NCT05411198 Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years o | Open-Angle Glaucoma | completed | 74 |
| 2026-01-26 | P2 | AbbVie ABBV | NCT04295538 Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acu | Spinal Cord Injury (SCI) | completed | 60 |
| 2026-01-05 est. | P3 | AbbVie ABBV | NCT06390722 A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis; Sleep Disturbance | withdrawn | |
| 2025-12-05 | P3 | AbbVie ABBV | NCT05818709 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants | Facial Volume Deficit | completed | 61 |
| 2025-12-01 | P3 | AbbVie ABBV | NCT04760769 Open-label Trial in Parkinson's Disease (PD) | Parkinson Disease | completed | 992 |
| 2025-11-25 | P3 | AbbVie ABBV | NCT06387394 A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence | Masseter Muscle Prominence | completed | 202 |
| 2025-11-20 | P3 | AbbVie ABBV | NCT06068855 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants | Masseter Muscle Prominence | completed | 249 |
| 2025-11-19 | P2 | AbbVie ABBV | NCT05291234 A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-9 | Alzheimer's Disease (AD) | completed | 106 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.